produce different analogs [8] . Recently, Professor Thorson's group has synthesized 37 different analogs of doxycycline glycoside analogs using the neoglycosylation approach [9] . Among the new analogs, a 2'-amino-α-D-glucoside-conjugated derivative exhibited activity comparable to doxycycline pharmacophore [9] . Because of the potential effect of sugar conjugation on doxycycline, we applied an enzymatic glycosylation approach to generate analogs of different tetracycline derivatives in this study. Moreover, the USFDA recently approved oritavancin, a semisynthetic lipoglycopeptide antibiotic, to treat adults with skin infections. The molecule possesses two 4-epi-vancosamines and a glucose monosaccharide in its structure. The 4-epivancosamine is believed to play a crucial role in exerting activity by interacting with peptides nearby, but distinct from the terminal D-alanyl-D-alanine (or D-lactate) in both S. aureus and enterococci [10] [11] [12] . Thus, oritavancin is active against vancomycin-resistant organisms. Dalbavancin and telavancin are other second-generation semisynthetic glycolipopeptides approved by the USFDA for treatment of skin infections [13] . Thus, glycosylation is attracting attention to conjugate diverse sugars to different lead molecules.
Most glycosylation post-modification reactions of natural products are performed by glycosyltransferase (GT) enzymes that can transfer the sugar moiety from an activated sugar donor to acceptor molecules [14, 15] . Several GTs that can conjugate sugars to small molecules have been identified from different sources, such as plants and microbes [16] . However, only a few sugar-conjugated tetracyclines are reported from natural sources. For example, dactylocycline derivatives [17] [18] [19] , TAN-1518 [20] , and SF2575 [21] are produced by different organisms (Fig. 1A) . In the last few years, we have found that a GT from Bacillus licheniformis DSM-13 (YjiC) has broad substrate flexibility. It is able to accept a wide range of small molecules as acceptors and different NDP-sugars as sugar donors [22] [23] [24] [25] [26] . We applied the same YjiC for in vitro glucosylation of selected natural and synthetic tetracycline analogs (Fig. 1B) using a single-vessel UDP-α-D-glucose recycling system (Fig. 2) . This is the first report of the production of tetracycline glucosides by an enzymatic glucosylation reaction. The generated molecules are most likely to be novel compounds.
Acetyl phosphate kinase (ACK) from Escherichia coli K-12 uses acetyl-Pi, and phosphorylates UDP to generate uridine triphosphate (UTP). Another enzyme, glucose 1-phosphate uridylyltransferase (GalU), also from the same species, transfers UDP from UTP to glucose 1-phosphate and produces UDP-α-D-glucose, which is the donor substrate for YjiC GT. Both glucose 1-phosphate and acetyl phosphate are commercially available at low cost.
Soluble fractions of the three proteins (ACK, GalU, and YjiC) were produced in the E. coli BL21(DE3) cytosol. The molecular mass was approximately 38 kDa for ACK and GalU and 45 kDa for YjiC. The respective bands of these soluble proteins were clearly observed by SDS-PAGE analysis (Fig. 3) . Detail methods for the protein expression and preparation are explained in the supporting materials.
Five different tetracycline derivatives (chlorotetracycline, doxytetracycline, meclotetracycline, minotetracycline, and rolitetracycline) purchased from Tokyo Chemical Industry The enzymes used in the one-pot reaction mixture are acetate kinase from E. coli K-12 (ACK), which converts UDP to UTP utilizing acetyl-1-phosphate; α-D-glucose 1-phosphate uridylyltransferase from E. coli K12 (GalU), which uses UTP and glucose-1-phosphate and generates UDP-α-D-glucose; and UDP-glycosyltransferase from B. licheniformis (YjiC), which transfers a glucose moiety from UDP-α-D-glucose to acceptor molecules such as tetracyclines. (Japan) were used for the in vitro single-vessel glucosylation reactions. The single-vessel reaction was carried out by putting all enzymes (ACK, GalU, YjiC) along with their required components for the reaction in 1 ml of final volume. For this reaction, each crude soluble protein fraction (~30 μg/ml of final concentration) was used. Other ingredients of the reaction mixture were 100 mM Tris-HCl buffer (pH 7.5) with 2 mM UDP-α-D-glucose, 2 mM each of tetracycline derivatives, 10 mM MgCl UPLC-PDA analysis showed novel peaks in four tetracycline analogs (chlorotetracycline, doxytetracycline, meclotetracycline, and minotetracycline) (Fig. 1B) . However, no novel peak was observed in the rolitetracycline derivative. Since novel peaks appeared in four different tetracyclines, the same reaction mixture was further analyzed by HR-QTOF ESI/MS to determine whether these new peaks might be possible glucoside derivatives of the respective tetracycline analog.
The standard chlorotetracycline appeared at the retention time (t R ) of 3.21 min. However, the novel peak supposed to be a glucoside derivative appeared at the lower t R of 2.35 min (Fig. 4(i) ). The maximum UV absorbance of each peak was determined. The λ m a x of standard chlorotetracycline was at 230, 268, and 371 nm (Fig. 4A(ii) ). However, it was shifted to 241 and 270 nm for the peak with t R of 2.35 min (Fig. 4A(iii) ). HR-QTOF ESI/MS analysis of the standard peak (t ( Fig. 4A(iv-v) ). This mass corresponded to the molecular mass of the glucose-conjugated chlorotetracycline derivative. The relative conversion percentage of chlorotetracycline to its glucoside was approximately 6%.
In the doxytetracycline reaction mixture, the doxytetracycline standard appeared at t R 3.30 min. However, a new peak assumed to be a glucoside derivative of doxytetracycline appeared at t R 2.32 min (Fig. 4B(i) ). Both peaks were further analyzed by spectroscopic and spectrometric analyses. Spectroscopic analysis revealed a similar pattern of UV absorbance maxima. The λ m a x for the standard doxytetracycline was at 269 and 348 nm. For the presumed glucoside derivative, it was at 268 and 339 nm (Fig. 4B(ii-iii) ). This analysis clearly showed that the new observed peak was a derivative of standard doxytetracycline. These peaks were further analyzed for their exact molecular masses. The standard peak showed a prominent spectrum of m/z + 445.1613 for which the calculated mass was 445.1611 Da for the molecular formula C 2 2
in the protonated state (Fig. 4B(iv) ). The new peak at t R 2.32 min showed a spectrum of m/z + 607.2132 (Fig. 4B(v) ) for which the calculated mass was 607.2139 Da for the molecular formula C . This exact mass resembles the mass of the monoglucosylated derivative of doxytetracycline. The conversion percentage of doxytetracycline was relatively small (below 3%).
The meclotetracycline reaction mixture showed the standard molecule at t R 3.54 min with a new peak at t R 2.51 min (Fig. 4C(i) ). The maxima UV absorbance of the standard molecule was at 243 and 346 nm for standard meclotetracycline. It was subtly changed to new peaks (at 240 and 339 nm) (Fig. 4C(ii-iii) ). These same peaks were further analyzed by HR-QTOF ESI/MS analysis to determine their exact molecular masses. As a result, the standard meclotetracycline at t (Fig. 4C(iv) ). The new peak in the UPLC at t for which the calculated exact mass was 639.1593 Da (Fig. 4C(v) ). Similar to the aforementioned tetracycline analogs, the reaction mixture of minotetracycline was also analyzed. In UPLC-PDA, the standard minotetracycline appeared at t R 2.59 min while a new peak appeared at t R 2.19 min (Fig. 4D(i) ). Both peaks had a similar pattern of UV absorbance maxima. The standard showed prominent λ (at 260 and 339 nm) (Fig. 4D(ii-iii) ). Mass spectrometry analysis of the standard showed the prominent spectrum of m/z + 458.1941, for which the molecular formula C in protonated mode (Fig. 4D(iv-v) ). UPLC-PDA analysis of the rolitetracycline reaction mixture did not show any new peaks (data not shown). Thus, the reaction mixture was not further analyzed by HR-QTOF ESI/MS. The conversion of substrates to products was relatively very small. Glucoside derivatives of doxytetracycline and meclotetracycline were produced in trace amount. In comparison with the other substrates, chlorotetracycline conversion to its glucoside was slightly higher. However, such quantity was not enough for structural analysis or biological activity determination. Thus, we did not scale up the reaction mixture of the tetracycline reactions for purification of the glucoside derivatives. Hence, further experiments for the complete structure elucidation and biological activities of the modified compounds were not performed.
Since the YjiC enzyme has been found to be very nonregiospecific for glucosylation reaction with small molecules [23, 27] , the prediction for the exact position of glucose conjugation to tetracycline analogs is difficult. However, in the case of tetracycline analogs, YjiC produced a single product for all molecules used in this study except for rolitetracycline, which was not accepted any longer for the reaction. The possible positions of glucose conjugation in tetracycline might be the OH-groups of all four rings (A-D). However, OH-groups of the B and C rings could be engaged in intramolecular H-bonding with adjacent keto functional groups. In the A-ring of tetracyclines, the OHgroup at the third position could be possibly hindered for glucosylation because of bulky methyl groups attached at the C-4 position and conceivable engagement of 3-OH to form H-bonding with neighboring amide functional groups present at the C-2 position. Thus, the glucose is most likely to be conjugated at the 10 t h -OH group in the D-ring of the tetracycline analogs used in this study.
In the in vitro glucosylation reaction, several problems have been reported for low bioconversion reaction, including the following: (i) competitive inhibition of binding of UDP-α-D-glucose to the donor substrate binding site by side products of the forward glucosylation reaction (i.e., UDP); (ii) reversible nature of the GT enzyme, which can hydrolyze the glucoside product to aglycone and UDP-α-Dglucose; (iii) low enzyme catalytic properties; and (iv) low enzyme preference toward acceptor substrates. It has been found that YjiC has high catalytic conversion efficiency in the forward direction with different acceptor substrates [23, 27] . However, it also exhibits a reversible glucosylation nature [24] . Thus, we applied the UDP-α-D-glucose recycling system for two main purposes: (i) to prevent competitive inhibition of binding of UDP-α-D-glucose by recycling UDP, and (ii) to prevent a reverse reaction. However, the conversion of tetracycline analogs to their respective glucosides has been found to be very low. This gives the clue that the enzyme has low preferences toward tetracycline molecules. Attachment of a bulky group in rolitetracycline might have prevented the molecule from reaching the catalytic cleft of GT. The results of this research could become a basis to explore the possibility of synthesizing glucosylated derivatives of different tetracyclines using the GT enzyme.
